Home > Boards > Stock Clubs > Long-Term > Billionaire Boys Club Member Forum (BBCMF)

On 18 March, Sunesis released the first assessments

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
mick Member Profile
Member Level 
Followed By 2,624
Posts 862,747
Boards Moderated 188
Alias Born 09/04/00
160x600 placeholder
mick Member Level  Thursday, 03/26/20 01:15:50 PM
Re: mick post# 508120
Post # of 508244 
On 18 March, Sunesis released the first assessments of the 400mg cohort in its ongoing dosing study of vecabrutinib for B-cell malignancies. Two (of three) patients in this cohort showed stable disease (SD), with one showing a 48% response. These results are largely similar to those seen with the 300mg cohort (one near-responder SD, two stabilized SD, and one progressor). We would like to have seen more definitive activity in this cohort, but there is still the possibility that Sunesis will cross the line of generating partial responses (PRs) in the upcoming 500mg cohort.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist